Cargando…

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

Epidermal growth factor receptor (EGFR) is a cell surface molecule and member of the ErbB family of receptor tyrosine kinases. Its activation leads to proliferation, antiapoptosis, and metastatic spread, making inhibition of this pathway a compelling target. In recent years, an increasing number of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harandi, Amir, Zaidi, Aisha S., Stocker, Abigail M., Laber, Damian A.
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2009
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2677718/ https://www.ncbi.nlm.nih.gov/pubmed/19424511 http://dx.doi.org/10.1155/2009/567486

Ejemplares similares

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
por: Melosky, Barbara, et al.
Publicado: (2014)

Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer
por: Flynn, John F., et al.
Publicado: (2009)

Heterogeneous EGFR Gene Copy Number Increase Is Common in Colorectal Cancer and Defines Response to Anti-EGFR Therapy
por: Ålgars, Annika, et al.
Publicado: (2014)

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
por: Derangère, Valentin, et al.
Publicado: (2016)

Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies
por: Giovannini, Monica, et al.
Publicado: (2009)

Remodeling of dermal adipose tissue alleviates cutaneous toxicity induced by anti-EGFR therapy
por: Chen, Leying, et al.
Publicado: (2022)

Unexpected insights for anti-EGFR cancer therapy
por: Depeille, Philippe, et al.
Publicado: (2015)

Lower toxicity and higher efficacy: a study on a novel fully human anti-EGFR antibody
por: Qiu, Weiyi, et al.
Publicado: (2015)

Update on Anti-EGFR Therapy
por: Chua, Daniel, et al.
Publicado: (2009)

Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone
por: ten Hoorn, Sanne, et al.
Publicado: (2021)

Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
por: Zhao, Ben, et al.
Publicado: (2016)

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review
por: Lacouture, Mario E., et al.
Publicado: (2017)

The DNA-polymorphism rs849142 is associated with skin toxicity induced by targeted anti-EGFR therapy using cetuximab
por: Froelich, Matthias F., et al.
Publicado: (2018)

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
por: Liu, X., et al.
Publicado: (2015)

Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer
por: Thomas, Brian J., et al.
Publicado: (2023)

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer
por: Fiore, F Di, et al.
Publicado: (2008)

Anti‐EGFR Therapy in Small Bowel Adenocarcinoma
por: Safyan, Rachael A., et al.
Publicado: (2018)

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer
por: Ålgars, A, et al.
Publicado: (2011)

Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept
por: Dragovich, Tomislav, et al.
Publicado: (2009)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma
por: Richard, Corentin, et al.
Publicado: (2018)

A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan
por: Qiu, Weiyi, et al.
Publicado: (2019)

Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?
por: Chiang, Ting-Yu, et al.
Publicado: (2023)

Anticoagulation With Platelet Transfusions for Acute Limb Ischemia With Severe Thrombocytopenia
por: Shakfeh, Khalid, et al.
Publicado: (2023)

Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru
por: Galvez‐Nino, Marco, et al.
Publicado: (2022)

The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon
por: Lee, Kun-Han, et al.
Publicado: (2021)

Treatment Protocols in the Efficacy and Safety of Anti-EGFR Medicines in Combination with Standard Therapy for Patients with Nasopharyngeal Cancer: A Meta-Analysis
por: Fang, Yakun, et al.
Publicado: (2023)

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade
por: Umelo, Ijeoma Adaku, et al.
Publicado: (2015)

EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted Therapy
por: Noronha, Vanita, et al.
Publicado: (2013)

Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials
por: Desai, Ruchi, et al.
Publicado: (2020)

Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
por: Fakih, M., et al.
Publicado: (2010)

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010)

Non-Coding RNAs Regulate the Resistance to Anti-EGFR Therapy in Colorectal Cancer
por: Chu, Jinjin, et al.
Publicado: (2022)

Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy
por: Si, Yingnan, et al.
Publicado: (2020)

AOHE: manuscript AOHE-D-16-00564 paroxysmal nocturnal hemoglobinuria with autoimmune hemolytic anemia following eculizumab therapy—with large granular lymphocytic leukemia
por: Visweshwar, Nathan, et al.
Publicado: (2016)

Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy
por: Lacouture, Mario E., et al.
Publicado: (2021)

Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation
por: Hoshi, Hirotaka, et al.
Publicado: (2017)

Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice
por: Steeghs, Elisabeth M P, et al.
Publicado: (2022)

The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling
por: Asbagh, Layka Abbasi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8ouma50rjvt8hv9uce2t5u9r4d